The information on this website is intended for healthcare professionals only and is provided for the purpose of scientific exchange.
The website is not country specific and may therefore contain information that is not applicable in your country, thus you may find information concerning study drugs or therapeutic uses that have not been approved by drug regulatory agencies. This website is not intended to promote in any way, any use, either approved, or unapproved, of a Novo Nordisk product or of any other product or serve as basis for any treatment decision or action. Please always refer to Summary of Product Characteristics (product label) as approved by regulatory authorities in your country or contact Novo Nordisk for further information.
Furthermore, the site is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. Only a physician can determine whether a specific product is correct for a particular patient. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site.
By accessing this website you accept this legal notice and expressly confirm your status as a healthcare professional.
Agnete Kirkeby is an Associate Professor and group leader at the Department of Neuroscience at University of Copenhagen (Denmark) and at the Wallenberg Center for Molecular Medicine at Lund University (Sweden). Agnete and her group has over the years built up a unique expertise in using human pluripotent stem cells for production of subtype-specific human neurons, and has developed protocols for accurate patterning of neural cells towards different regional fates (Kirkeby et al., Cell Reports 2012). This work has led to the development of a promising stem cell treatment for Parkinson’s Disease (PD), which is moving towards clinical trial in collaboration with Prof. Malin Parmar at Lund University, Prof. Roger Barker at Cambridge University and Novo Nordisk A/S (Kirkeby et al., Cell Stem Cell 2017, Nolbrant et al., Nature Protocols 2017, Kirkeby et al., Prog. Brain Research 2017).
The Kirkeby group further studies early brain development using human stem cell and advanced microfluidic culturing techniques to model the developing neural tube of humans, and produce various different types of neurons (i.e. hypothalamic neurons, interneurons, basal forebrain cholinergic neurons) for use in regenerative therapy and disease modelling.